Adaptimmune Therapeutics PLC expected to post a loss of 22  cents a share - Earnings Preview

Adaptimmune Therapeutics

29/04/2022 23:16

* Adaptimmune Therapeutics PLC  ADAP.OQ   ADAP.O  is
expected
to show a rise in quarterly revenue when it reports  results on
May 3 (estimated). 
    * The Abingdon Oxfordshire-based  company is expected to
report  a
657.1% increase in revenue to $3.286 million from $434 thousand
a year ago, according to the mean estimate from 7 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Adaptimmune
Therapeutics
PLC is for a loss of 22 cents per share. For the same quarter
last year, the company reported a loss of 24 cents per share.
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 4
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 6.1%
in the last three months. ​
    * Wall Street's median 12-month price target for Adaptimmune
Therapeutics PLC is $7​, above​ its last closing price of $1.72.
​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2021  0.26        0.14       -0.24     Missed  -271.4
 Sep. 30 2021  -0.26       -0.26      -0.30     Missed  -13.2
 Jun. 30 2021  -0.24       -0.24      -0.24     Met     2​
 Mar. 31 2021  -0.25       -0.25      -0.24     Beat    4
 ​​Dec.        -0.23       -0.23      -0.24     Missed  -3.3
 31 2020                                                
 Sep. 30 2020  -0.25       -0.25      -0.24     Beat    5.5​
 Jun. 30 2020  -0.24       -0.24      -0.24     Met     -2
 Mar. 31 2020  -0.26       -0.25      -0.24     Beat    5.3
 This summary was machine generated April 29 at 22:16 GMT.  All
figures in US dollars  unless otherwise stated